J. Woolmore

发表

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

D. Arnold, S. Muley, P. Vermersch, 2018, The Lancet Neurology.

Measuring coping in multiple sclerosis: The Coping Index-MS

A. Tennant, B. Sharrack, C. Young, 2022, Multiple sclerosis.

Disability, depression and suicide ideation in people with multiple sclerosis.

T. Powell, J. Woolmore, C. Jones, 2017, Journal of affective disorders.

Post Vaccination Optic Neuritis: Observations From the SARS-CoV-2 Pandemic

F. Paul, C. Tilikete, A. Toosy, 2021, SSRN Electronic Journal.

The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications

A. Tennant, B. Sharrack, C. Constantinescu, 2022, Journal of the Neurological Sciences.

Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy

A. Tennant, B. Sharrack, C. Constantinescu, 2021, Journal of the Neurological Sciences.

The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome

A. Tennant, J. Woolmore, C. Hawkins, 2012, Multiple sclerosis.

University of Birmingham Disability, Depression and Suicide Ideation in People with Multiple Sclerosis

J. Woolmore, K. Williamsa, C. KoKo, 2016 .

Prevalence, treatment and correlates of depression in multiple sclerosis.

Radu Tanasescu, J. Woolmore, R. Mills, 2024, Multiple sclerosis and related disorders.